IN-VITRO AND IN-VIVO ACTIVITY OF TOPOTECAN AGAINST HUMAN B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS

被引:53
作者
UCKUN, FM
STEWART, CF
REAMAN, G
CHELSTROM, LM
JIN, JH
CHANDANLANGLIE, M
WADDICK, KG
WHITE, J
EVANS, WE
机构
[1] UNIV MINNESOTA, DEPT PHARMACOL, MINNEAPOLIS, MN 55455 USA
[2] UNIV MINNESOTA, DEPT PEDIAT, MINNEAPOLIS, MN 55455 USA
[3] UNIV MINNESOTA, DEPT LAB MED PATHOL, MINNEAPOLIS, MN 55455 USA
[4] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38105 USA
[5] CHILDRENS NATL MED CTR, DEPT HEMATOL ONCOL, WASHINGTON, DC 20010 USA
[6] CHILDRENS CANC RES GRP, ARCADIA, CA USA
关键词
D O I
10.1182/blood.V85.10.2817.bloodjournal85102817
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Topotecan [(S)-9-dimethylaminomethyl-10-hydroxycamptothecin hydrochloride; SK&F 104864-A, NSC 609699], a water soluble semisynthetic analogue of the alkaloid camptothecin, is a potent topoisomerase I inhibitor. Here we show that topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell in vitro clonogenic growth in a dose-depen-dent fash ion. Furthermore, topotecan elicited potent antileukemic activity in three different severe combined immunodeficiency (SCID) mouse models of human poor prognosis ALL and markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of human leukemia cells at systemic drug exposure levels that can be easily achieved in children with leukemia. (C) 1995 by The American Society of Hematology.
引用
收藏
页码:2817 / 2828
页数:12
相关论文
共 43 条
[1]   CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I [J].
ANDOH, T ;
ISHII, K ;
SUZUKI, Y ;
IKEGAMI, Y ;
KUSUNOKI, Y ;
TAKEMOTO, Y ;
OKADA, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5565-5569
[2]   ACTIVATION OF PROGRAMMED CELL-DEATH (APOPTOSIS) BY CISPLATIN, OTHER ANTICANCER DRUGS, TOXINS AND HYPERTHERMIA [J].
BARRY, MA ;
BEHNKE, CA ;
EASTMAN, A .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (10) :2353-2362
[3]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ANALYSIS OF THE NEW ANTITUMOR DRUG SK-AND-F 104864-A (NSC 609699) IN PLASMA [J].
BEIJNEN, JH ;
SMITH, BR ;
KEIJER, WJ ;
VANGIJN, R ;
HUININK, WWT ;
VLASVELD, LT ;
RODENHUIS, S ;
UNDERBERG, WJM .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (8-12) :789-794
[4]  
BLANEY SM, 1993, CANCER RES, V53, P1032
[5]   THE STAGING OF CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - STRATEGIES OF THE CHILDRENS CANCER STUDY-GROUP AND A 3-DIMENSIONAL TECHNIQUE OF MULTIVARIATE-ANALYSIS [J].
BLEYER, WA ;
SATHER, H ;
COCCIA, P ;
LUKENS, J ;
SIEGEL, S ;
HAMMOND, GD .
MEDICAL AND PEDIATRIC ONCOLOGY, 1986, 14 (05) :271-280
[6]  
CHAMPLIN R, 1989, BLOOD, V73, P2051
[7]  
COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6
[8]  
DARGENIO DZ, 1990, ADAPT II USERS GUIDE
[9]  
GAYNON PS, 1988, AM J PEDIAT HEMATOL, V10, P42
[10]   BCL-2 IS AN INNER MITOCHONDRIAL-MEMBRANE PROTEIN THAT BLOCKS PROGRAMMED CELL-DEATH [J].
HOCKENBERY, D ;
NUNEZ, G ;
MILLIMAN, C ;
SCHREIBER, RD ;
KORSMEYER, SJ .
NATURE, 1990, 348 (6299) :334-336